Objective-Patients with familial hypercholesterolemia (FH) are at high risk for premature atherosclerotic cardiovascular disease (ASCVD), especially because of long-term exposure to high low-density lipoprotein cholesterol levels. It has been reported that low-density lipoprotein-lowering therapy delays the onset of ASCVD. However, it still remains difficult to prevent it. Therefore, novel biomarkers and therapeutic targets are necessary to evaluate and prevent atherosclerosis in FH. 
F amilial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by a life-long elevated plasma concentration of low-density lipoprotein-cholesterol (LDL-C), the presence of tendon xanthomas, and increased risk of premature atherosclerotic cardiovascular disease (ASCVD). 1 FH is caused by mutations in the LDL receptor and its related genes. 2 These mutations lead to a reduced number of functional LDL receptors, resulting in decreased cellular uptake of LDL, increased plasma LDL-C concentrations, and cholesterol accumulation in macrophages within the arterial wall. 3 Once diagnosed, patients with FH are treated with cholesterol-lowering medication, as represented by statins, to prevent development of atherosclerosis. Robust lowering of LDL-C levels is essential for reducing risk of premature ASCVD and early death. We have previously reported that statin treatment improved the clinical course of patients with heterozygous FH. 4 However, only a small proportion of patients with FH reaches the LDL-C treatment target, 5, 6 and it is sometimes difficult to prevent the development of ASCVD even with aggressive cholesterol-lowering therapy.
Other traditional risk factors, such as age, male sex, smoking, hypertension, diabetes mellitus, and low high-density lipoprotein-cholesterol (HDL-C) 7, 8 have been reported to be important for ASCVD in heterozygous FH. We have reported that pretreatment levels of LDL-C and Achilles tendon thickness were useful risk markers for determining patients at high risk for ASCVD in heterozygous FH. 9 Lipoprotein(a), 10, 11 homocysteine, 12 and family history of ASCVD 9 have also been identified as risk factors. Among the risk factors, concentration of plasma HDL-C is a potential candidate for reduction of residual risks after statin treatment in patients with heterozygous FH.
The concentration of plasma HDL-C is inversely related to the risk of ASCVD as demonstrated by numerous epidemiological studies. 13 The atheroprotective effect of HDL is largely attributed to its key role in a process called reverse cholesterol transport, whereby excess cholesterol from foamy macrophages is transported back to the liver for subsequent conversion to bile. [14] [15] [16] [17] However, pharmacological interventions that increase HDL-C levels have not improved cardiovascular outcomes when added to standard therapy. [18] [19] [20] Recently, it has been reported that the ability of HDL to promote cholesterol efflux from macrophages, the first step in the reverse cholesterol transport pathway, is inversely associated with risk for ASCVD even after adjusting for HDL-C, 21 providing supporting evidence for the importance of HDL functionality over the simple measurement of HDL-C levels.
To date, a few studies have helped clarify the mechanism of reverse cholesterol transport in patients with FH. Nenseter et al 22 revealed that cholesterol efflux capacity in patients with homozygous FH was reduced when compared with healthy controls, and Bellanger et al 7 demonstrated that large HDL2 particles isolated from 12 patients with FH displayed reduced cholesterol efflux capacity when compared with 12 healthy normolipidemic subjects. However, it had not been investigated whether cholesterol efflux capacity is a risk marker of ASCVD in patients with FH.
Accordingly, the present study was performed to investigate relationships between cholesterol efflux capacity and clinical features, including corneal arcus, Achilles tendon thickness, subclinical atherosclerosis, and presence of ASCVD, in patients with heterozygous FH under treatment.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Study Population
The characteristics of the 227 FH patients with or without ASCVD are shown in Table 1 . Seventy-six (33.5%) patients among them were known to have ASCVD. ASCVD was considered to be present if subjects met one of the following criteria: (1) myocardial infarction proven by ECG abnormalities and enzyme changes; (2) symptomatic ischemic stroke identified by computed tomogram or magnetic resonance imaging; (3) diagnosis of angina pectoris with significant stenosis >75% on coronary angiogram; (4) coronary bypass surgery or percutaneous coronary interventions. There were 36 patients with myocardial infarction, 12 patients with symptomatic ischemic stroke, 33 patients with angina who had undergone either coronary bypass surgery or percutaneous coronary interventions, and 4 patients with coronary stenosis without any revascularization. Nine of the patients with ischemic stroke previously had coronary heart diseases.
Among the 227 patients with FH, 88 (38.8%) had lossof-function mutation in LDL receptor, 7 (3.1%) had gain-offunction mutation in proprotein convertase subtilisin/kexin type 9 (PCSK9), 11 (4.8%) had both, 80 (35.2%) patients were genotype absent, 26 (11.5%) patients had not undergone genetic testing, and 15 (6.6%) patients were under examination. The genotype absent patients were clinically diagnosed as heterozygous FH using diagnostic criteria for adult heterozygous FH described in Japanese guidelines for the management of FH. 23 Patients with ASCVD were older and had, on average, higher body mass indexes, in addition to a higher prevalence of hypertension and diabetes mellitus, than those without ASCVD. There were many more patients with smoking history in the ASCVD group. Mean levels of HDL-C and ApoAI were lower in patients with ASCVD, whereas the median triglycerides level was significantly higher. Furthermore, prevalence of corneal arcus, mean Achilles tendon thickness, and mean carotid intimamedia thickness (IMT) were greater in patients with ASCVD.
Cholesterol Efflux Capacity in Patients With FH
The mean values for cholesterol efflux capacity after normalization to the value of the pooled sample were 0.88±0.14 (range, 0.40-1.22) in patients with FH. Scatterplot analyses revealed significant correlations between cholesterol efflux capacity and levels of both HDL-C (r = 0.83; P<0.0001) and ApoAI (r = 0.83; P<0.0001; Figure I in the online-only Data Supplement). We conducted a linear regression with all risk factors to clarify correlations with cholesterol efflux capacity in aggregate. Probucol use, Log triglycerides, and having both LDL receptor and proprotein convertase subtilisin/kexin type 9 mutations were associated with reduced cholesterol efflux capacity, whereas genotype absence was related to increased cholesterol efflux capacity (Table 2 , model 1). After the addition of the presence of corneal arcus, Achilles tendon thickness, mean carotid IMT, and the presence of ASCVD as covariates, probucol use, Log triglycerides, and the presence of ASCVD were associated with reduced cholesterol efflux capacity (Table 2, model 2).
Association Between ASCVD and Cholesterol Efflux Capacity
In patients with ASCVD, the mean cholesterol efflux capacity after normalization to the value of the pooled sample was significantly lower than in patients without ASCVD (0.80±0.14 versus 0.92±0.11, respectively; P<0.0001; Table 1 ). In a logistic-regression analysis adjusted for age, sex, and traditional cardiovascular risk factors (smoking history [current and past], the presence of hypertension, the presence of diabetes mellitus, the presence of obesity [body mass index, ≥25 kg/m 2 , LDL-C, and Log triglycerides), increased efflux capacity was associated with decreased risk of ASCVD even after the addition of HDL-C level as a covariate (odds ratio [OR] per 1-SD increase, 0.95; 95% confidence interval [CI], 0.90-0.99; P=0.0260; Table 3 ). The results were similar when the ApoAI level was substituted for the HDL-C level (OR per 1-SD increase, 0.95; 95% CI, 0.90-1.00; P=0.0470). Moreover, this relationship remained robust even after additional adjustment for probucol use (Table I in the online-only Data Supplement). Among known cardiovascular risk factors, the presence of hypertension was also associated with presence of ASCVD (Table 3) .
Association Between Corneal Arcus and Cholesterol Efflux Capacity
Patients with corneal arcus had lower cholesterol efflux capacity than those without (0.84±0. 15 respectively; P=0.0002; Table 4 ). Because it has been reported that the prevalence of corneal arcus increases with advancing age and is lower in women, we conducted the logistic analysis adjusting for age and sex. As a result, decreased cholesterol efflux capacity was associated with the presence of corneal arcus (OR per 1-SD increase, 0.98; 95% 
Association Between Achilles Tendon Thickness and Cholesterol Efflux Capacity
Patient characteristics according to tertiles of Achilles tendon thickness are presented in Table 5 . Cholesterol efflux capacity was inversely associated with Achilles tendon thickness (P<0.0001 for linear trend across tertiles). A significant inverse relationship between cholesterol efflux capacity and Achilles tendon thickness was observed even in multivariate analysis after adjustment for age, sex, and traditional cardiovascular risk factors. However, subsequent adjustment for HDL-C or ApoAI levels attenuated this relationship (Table III in the online-only Data Supplement). In the linear regression analysis, male sex (β=0.82; 95% CI, 0.01-1.63; P=0.0472), and LDL-C levels (β=0.02; 95% CI, 0.0006-0.04; P=0.0411) were associated with an increase in Achilles tendon thickness.
Association Between Subclinical Atherosclerosis and Cholesterol Efflux Capacity
Patient characteristics according to tertiles of mean carotid IMT (mean-IMT) are presented in Table 6 . Cholesterol efflux capacity was inversely associated with mean-IMT (P<0.0001 for linear trend across tertiles). A significant inverse relationship between cholesterol efflux capacity and mean carotid IMT was observed even in multivariate analysis after adjustment for age, sex, and traditional cardiovascular risk factors. However, subsequent adjustment for HDL-C or ApoAI levels attenuated this relationship in analogy with Achilles tendon thickness (Table IV in the online-only Data Supplement). In the linear regression analysis, we found that ApoAI levels were independently and inversely associated with mean IMT (β=−0.005; 95% CI, −0.01 to −0.001; P=0.0157). In addition, age (β=0.18; 95% CI, 0.013-0.023; P<0.0001) and the presence of hypertension (β=0.08; 95% CI, 0.003-0.16; P=0.0412) were associated with mean carotid IMT.
Discussion
The main finding of the present study was that decreased cholesterol efflux capacity was associated with increased risk of ASCVD even in statin-treated patients with FH. In addition, we found that patients with corneal arcus had lower cholesterol efflux capacity after adjustment for age and sex. There was also an inverse association of cholesterol efflux capacity with Achilles tendon thickness as well one with carotid IMT after adjustment for age, sex, and traditional cardiovascular risk factors. However, these associations diminished after additional adjustment for HDL or ApoAI.
We and other researchers have reported that the presence of corneal arcus or tendon xanthomas is associated with higher risk for ASCVD in patients with FH, 9,24,25 suggesting that corneal arcus, xanthomas, and atherosclerosis are related and have similar mechanisms of cholesterol accumulation. However, it had not been evident previously whether capacity for cholesterol removal from cornea and Achilles tendon xanthomas is associated with their presence and thickness. In the present study, we observed both reduced cholesterol efflux capacity in patients with corneal arcus and an inverse relationship between cholesterol efflux capacity and Achilles tendon thickness in patients with FH. Importantly, decreased cholesterol efflux capacity was associated with the presence of corneal arcus even after adjustment for age and sex. In addition, the inverse association between Achilles tendon thickness and cholesterol efflux capacity remained robust after adjustment for age, sex, and traditional cardiovascular risk factors. Although these relationships were attenuated after additional adjustment for HDL-C levels, we consider our finding to be clinically important and provide a novel insight into our current understanding of corneal arcus and xanthoma formation in FH. Interestingly, it was reported that corneal arcus was related to not only low concentrations of HDL-C 26 but also cigarette smoking 27 and obesity. 28 A relationship between smoking history and corneal arcus was also observed in the present study. Oosterveer et al 24 reported that the presence of tendon xanthomas in patients with FH is associated with genetic variation in the randomized controlled trials and LDL oxidation pathways. Moreover, Artieda et al 29 reported that tendon xanthoma formation might be associated with higher intracellular lipid content, and a stronger inflammatory response of macrophages to oxidized LDL. Accordingly, we speculate that, in addition to cholesterol efflux capacity, the antioxidative and anti-inflammatory properties of HDL might play a significant role in the formation of corneal arcus and Achilles tendon xanthomas.
We also demonstrated that there was an inverse relationship between cholesterol efflux capacity and mean carotid IMT in the 227 patients with FH. This reinforces the finding of a recent study that there was a significant inverse relationship between cholesterol efflux capacity and carotid IMT in 12 patients with FH. 7 The relationship in our study was attenuated after additional adjustment for HDL-C or ApoAI levels. Furthermore, we found that ApoAI levels remained a strong predictor for max-and mean IMT. In this regard, Junyent et al 30 have reported that the HDL-C level and total cholesterol/ HDL ratio are strong predictors of preclinical carotid atherosclerosis in patients with heterozygous FH. Therefore, our observations strengthen the evidence for the quantities of HDL and ApoAI being important risk markers for preclinical atherosclerosis. On the contrary, Doonan et al 31 have reported an inverse association between cholesterol efflux capacity and carotid stenosis after adjusting for HDL-C or ApoAI levels in patients with high-grade carotid stenosis. In their study, only modest correlations between cholesterol efflux capacity and HDL-C (r = 0.27) and ApoAI (r = 0.361) were observed, whereas we found significant relationships between cholesterol efflux capacity and both HDL-C (r = 0.83) and ApoAI (r = 0.83; Figure I in the online-only Data Supplement). These differences might be the reason why ApoAI quantity was a stronger predictor than cholesterol efflux capacity in our study.
This study show that FH subjects with ASCVD have significantly less cholesterol efflux capacity when compared with those without ASCVD. Importantly, this relationship was robust even after adjustment for HDL-C or ApoAI levels, and despite the fact that all subjects were treated with statins. In consideration of residual risk reduction, our observations suggest that cholesterol efflux capacity might be a novel biomarker and a therapeutic target for preventing atherosclerosis in patients with FH under aggressive lipid-lowering treatment. Recently, Rohatgi et al 32 have shown that cholesterol efflux capacity was inversely associated with the incidence of cardiovascular events in a population-based cohort. Accordingly, in the future, it would be important to clearly establish causation by following up patients with FH to determine whether cholesterol efflux capacity is associated with progression of atherosclerosis. In addition, when considering secondary prevention in FH subjects with ASCVD, it is important to pay attention to their lower cholesterol efflux capacity. Patel et al 33 recently demonstrated in a study on patients with angina pectoris that those with ischemic heart failure had lower HDL concentrations and also impaired HDL functions, including antioxidative and cholesterol efflux capacity, implying that impairment of HDL functions may contribute to complications of ASCVD. Therefore, it remains to be investigated whether therapies targeting quality of HDL could be effective for preventing atherosclerosis and recurrence of ASCVD in patients with FH.
The mechanisms underlying our observation that cholesterol efflux capacity was a stronger predictor for the presence of ASCVD than HDL quantity remain to be elucidated. We speculate that considerable heterogeneity in protein and lipid composition of HDL might have an influence. Recently, Shao et al 34 have shown that there was a significant correlation between levels of post-translationally modified ApoAI, including that in which there has been chlorination of the tyrosine residue at position 192 and oxidation of methionine 148 (Met (O) 148), and HDL-C efflux capacity, and that levels of Met (O) 148 had the highest OR for cardiovascular disease status. In addition, HDL phospholipid composition has been positively associated with cholesterol efflux capacity. 7, 35, 36 Therefore, identification of ApoAI modification and HDL phospholipid composition in patients with FH would provide important information for predicting ASCVD risks.
The hypolipidemic drug probucol is generally prescribed to patients who cannot be effectively treated with statins and ezetimibe only. It is known to reduce plasma HDL 37, 38 by inhibiting ATP-binding cassette transporter A1-mediated HDL biogenesis. 39 We observed that patients who had been treated with probucol had significantly lower cholesterol efflux capacity than those who had not, which leads us to speculate that patients with severe ASCVD might have received higher doses of probucol. On the contrary, probucol has been reported to reduce atherosclerosis in animal models 40, 41 and xanthomas in humans. 42 Therefore, in our multivariate analysis, we added probucol as a covariate and it did not affect the relationship between cholesterol efflux capacity and the presence of ASCVD (Table I in the online-only Data Supplement) or Achilles tendon thickness (data not shown).
Our study has several limitations. First, it had a crosssectional design. Therefore, we could only demonstrate associations and not causal relationships. Second, the cholesterol efflux capacity assay quantifies not only 1 component of the reverse cholesterol transport pathway but also 1 property among several atheroprotective functions of HDL, including anti-inflammatory and antioxidative effects. Third, we did not measure LDL-C levels before any lipid-lowering therapy was initiated, and the duration of the untreated period was not considered. Therefore, pretreatment levels of LDL-C as a risk factor for ASCVD might have been underestimated. Finally, we could not exclude the possibility that other medications might have affected lipids and cholesterol efflux as well.
In conclusion, our findings strengthen the concept that assessment of HDL function may provide more information about HDL-mediated atheroprotection in patients with FH. In addition, our findings strongly support the concept that enhancement of HDL functions could be a promising strategy in the treatment of patients with FH by inducing removal of cholesterol from peripheral tissues, including that in the cornea, xanthomas, and the arterial wall.
